Israel’s Lutris is developing a topical B-Raf Inhibitor LUT014 – a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to cancer patients without interruptions caused by skin problems.
Reducing side-effects of cancer therapy
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.